Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic SyndromesValeria Santini, Maria Domenica Cappellini, Domenico Girelli et al.|PLoS ONE|2011Cited by 136
Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre studyPellegrino Musto, Alessandro Levis, Luca Maurillo et al.|British Journal of Haematology|2017Cited by 25
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Francesca Romana Mauro, Gianluigi Reda et al.|Leukemia|2025Cited by 5
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Lara Crucitti, Andrea Galitzia et al.|Haematologica|2025Cited by 2
Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)Enrico Tiacci, Monia Capponi, Andrea Bernardelli et al.|HemaSphere|2025Cited by 1